Oncotarget

Research Papers:

Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice

Qing Zhang, Haiyu Wang, Huizhong Li, Jinjing Xu, Kang Tian, Jie Yang, Zheng Lu and Junnian Zheng _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:9488-9499. https://doi.org/10.18632/oncotarget.14367

Metrics: PDF 1844 views  |   HTML 2148 views  |   ?  


Abstract

Qing Zhang1,*, Haiyu Wang1,*, Huizhong Li1, Jinjing Xu1, Kang Tian1, Jie Yang1, Zheng Lu1, Junnian Zheng1,2

1Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, 221002, China

2Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical College, Xuzhou, Jiangsu, 221002, China

*These authors contributed equally to this work

Correspondence to:

Junnian Zheng, email: jnzheng@xzmc.edu.cn

Keywords: chimeric antigen receptor, T cell, tissue factor, lung cancer, melanoma

Received: June 17, 2016     Accepted: December 05, 2016     Published: December 30, 2016

ABSTRACT

Chimeric antigen receptor (CAR)-modified T cell (CAR T) is a promising therapeutic option for patients with cancer. Such an approach requires the identification of tumor-specific antigen targets that are expressed in solid tumors. We developed a new third-generation CAR directed against tissue factor (TF), a surface molecule overexpressed in some types of lung cancer, melanoma and other cancers. First, we demonstrated by immunohistochemistry that TF was overexpressed in squamous cell carcinoma and adenocarcinoma of non-small cell lung cancer (NSCLC) and melanoma using a human tissue microarray. In the presence of TF-positive cancer cells, the CAR-modified T cells (TF-CAR T) were highly activated and showed specific cytotoxicity to TF-positive cancer cells in vitro. In established s.c. xenograft and lung metastasis models, TF-CAR T cells could significantly suppress the growth of s.c. xenograft and metastasis of TF-positive cancer cells. Additionally, the safety evaluation of TF-CAR T cells in vivo showed that the treatment did not cause obvious toxicity in mice. Taken together, these findings indicate that TF-CAR T cells might be a novel potential therapeutic agent for the treatment of patients with TF-positive cancers.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 14367